JP6854073B2 - 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 - Google Patents
表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 Download PDFInfo
- Publication number
- JP6854073B2 JP6854073B2 JP2015044097A JP2015044097A JP6854073B2 JP 6854073 B2 JP6854073 B2 JP 6854073B2 JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015044097 A JP2015044097 A JP 2015044097A JP 6854073 B2 JP6854073 B2 JP 6854073B2
- Authority
- JP
- Japan
- Prior art keywords
- serine
- barrier function
- racemase
- amount
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 title claims description 101
- 229930195711 D-Serine Natural products 0.000 title claims description 100
- 108010006152 Serine racemase Proteins 0.000 title claims description 100
- 102100035717 Serine racemase Human genes 0.000 title claims description 97
- 239000003814 drug Substances 0.000 title claims description 80
- 238000000034 method Methods 0.000 title claims description 80
- 229940079593 drug Drugs 0.000 title claims description 76
- 230000008591 skin barrier function Effects 0.000 title claims description 76
- 238000012216 screening Methods 0.000 title claims description 44
- 230000002708 enhancing effect Effects 0.000 title claims description 40
- 238000011156 evaluation Methods 0.000 title description 8
- 230000014509 gene expression Effects 0.000 claims description 80
- 230000000694 effects Effects 0.000 claims description 74
- 210000002510 keratinocyte Anatomy 0.000 claims description 67
- 210000003491 skin Anatomy 0.000 claims description 53
- 230000004888 barrier function Effects 0.000 claims description 35
- 230000004069 differentiation Effects 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 210000000434 stratum corneum Anatomy 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 150000008574 D-amino acids Chemical class 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 11
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 description 59
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 54
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 45
- 239000002609 medium Substances 0.000 description 36
- 229960001153 serine Drugs 0.000 description 32
- 239000000284 extract Substances 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 23
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 23
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 23
- 229960001327 pyridoxal phosphate Drugs 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 108090001066 Racemases and epimerases Proteins 0.000 description 18
- 102000004879 Racemases and epimerases Human genes 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 230000003287 optical effect Effects 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 239000002537 cosmetic Substances 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 101710088660 Filaggrin Proteins 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102100028314 Filaggrin Human genes 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 210000002615 epidermis Anatomy 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 235000007319 Avena orientalis Nutrition 0.000 description 9
- 244000075850 Avena orientalis Species 0.000 description 9
- 101710148705 Cornulin Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- -1 vitamin B 6 compound Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 8
- PGZIDERTDJHJFY-UHFFFAOYSA-N 4-fluoro-7-nitro-2,1,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=C(F)C2=NON=C12 PGZIDERTDJHJFY-UHFFFAOYSA-N 0.000 description 8
- 241001317575 Elephantopus Species 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000012190 activator Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 102100032202 Cornulin Human genes 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000208838 Asteraceae Species 0.000 description 5
- 241000209219 Hordeum Species 0.000 description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- 241000234314 Zingiber Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000004264 monolayer culture Methods 0.000 description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 4
- 210000000498 stratum granulosum Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 241000234299 Zingiberaceae Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229960003581 pyridoxal Drugs 0.000 description 3
- 235000008164 pyridoxal Nutrition 0.000 description 3
- 239000011674 pyridoxal Substances 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100026259 Repetin Human genes 0.000 description 2
- 101710147968 Repetin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000007159 enucleation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 210000004565 granule cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 102000007236 involucrin Human genes 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 210000000437 stratum spinosum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 2
- 102100021206 60S ribosomal protein L19 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000006534 Amino Acid Isomerases Human genes 0.000 description 1
- 108010008830 Amino Acid Isomerases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000788084 Escualosa thoracata Species 0.000 description 1
- 108700041153 Filaggrin Proteins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001079803 Homo sapiens 39S ribosomal protein L19, mitochondrial Proteins 0.000 description 1
- 101001105789 Homo sapiens 60S ribosomal protein L19 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 1
- 108010070514 Keratin-1 Proteins 0.000 description 1
- 108010065038 Keratin-10 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 241001125048 Sardina Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000059271 Zingiber aromaticum Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- RCYWWJBNPIWJMJ-UHFFFAOYSA-N [4-(hexadecanoyloxymethyl)-5-hydroxy-6-methylpyridin-3-yl]methyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC1=CN=C(C)C(O)=C1COC(=O)CCCCCCCCCCCCCCC RCYWWJBNPIWJMJ-UHFFFAOYSA-N 0.000 description 1
- GQJPGCPNWFZCPD-UHFFFAOYSA-N [5-(2-hexyldecanoyloxy)-4-(2-hexyldecanoyloxymethyl)-6-methylpyridin-3-yl]methyl 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OCC1=CN=C(C)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1COC(=O)C(CCCCCC)CCCCCCCC GQJPGCPNWFZCPD-UHFFFAOYSA-N 0.000 description 1
- PAUSGZCRNOTKPK-UHFFFAOYSA-N [5-hydroxy-6-methyl-4-(octanoyloxymethyl)pyridin-3-yl]methyl octanoate Chemical compound CCCCCCCC(=O)OCC1=CN=C(C)C(O)=C1COC(=O)CCCCCCC PAUSGZCRNOTKPK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 229940095042 pyridoxine dipalmitate Drugs 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000024351 regulation of hormone secretion Effects 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015044097A JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
| JP2019186327A JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014043073 | 2014-03-05 | ||
| JP2014043073 | 2014-03-05 | ||
| JP2015044097A JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186327A Division JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015180198A JP2015180198A (ja) | 2015-10-15 |
| JP2015180198A5 JP2015180198A5 (enExample) | 2016-04-28 |
| JP6854073B2 true JP6854073B2 (ja) | 2021-04-07 |
Family
ID=54328827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015044097A Active JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
| JP2019186327A Active JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186327A Active JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6854073B2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7172984B2 (ja) * | 2017-03-24 | 2022-11-16 | 味の素株式会社 | 角層機能改善剤 |
| JP7366428B2 (ja) * | 2018-08-27 | 2023-10-23 | Kagami株式会社 | 乾癬を判定するための皮膚試料の分析方法及びシステム |
| JP7237689B2 (ja) * | 2019-03-28 | 2023-03-13 | 株式会社ナリス化粧品 | ストレスに起因する皮膚バリア機能改善剤のスクリーニング方法 |
| JP2023056255A (ja) * | 2021-10-07 | 2023-04-19 | エスエス製薬株式会社 | 色素斑形成抑制剤、メラノソーム貪食亢進抑制剤及び表皮分化能改善剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4202638B2 (ja) * | 2001-12-12 | 2008-12-24 | 丸善製薬株式会社 | コラーゲン産生促進剤、エラスターゼ阻害剤、コラゲナーゼ阻害剤及び老化防止用皮膚化粧料 |
| JP2005041861A (ja) * | 2003-07-09 | 2005-02-17 | Takeda Chem Ind Ltd | 皮膚角層水分量低下抑制剤 |
| JP5795960B2 (ja) * | 2009-09-14 | 2015-10-14 | 株式会社 資生堂 | 紫外線障害軽減組成物 |
-
2015
- 2015-03-05 JP JP2015044097A patent/JP6854073B2/ja active Active
-
2019
- 2019-10-09 JP JP2019186327A patent/JP6934925B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015180198A (ja) | 2015-10-15 |
| JP6934925B2 (ja) | 2021-09-15 |
| JP2020000257A (ja) | 2020-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6934925B2 (ja) | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 | |
| JP5235439B2 (ja) | ＨＭＧ−ＣｏＡ還元酵素産生促進剤 | |
| EP2618808B1 (fr) | Utilisation cosmétique de la dermcidine ou fragments de celle-ci | |
| CA2909573A1 (fr) | Utilisation de biomarqueurs de la barriere pour l'evaluation de l'efficacite d'actifs | |
| Meunier et al. | From stem cells protection to skin microbiota balance: Orobanche rapum extract, a new natural strategy | |
| JP5737663B2 (ja) | 皮膚バリア機能改善剤 | |
| JP7116589B2 (ja) | Ｄｉｓｃｏｉｄｉｎ Ｄｏｍａｉｎ Ｒｅｃｅｐｔｏｒ２（ＤＤＲ２）産生促進用組成物 | |
| US10907208B2 (en) | Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or D-serine level as indicator | |
| EP4486867A1 (fr) | Modele de peau reconstituee | |
| EP3049809B1 (fr) | Procédés d'évaluation des effets délétères des uv sur la peau d'enfant | |
| JP2022515623A (ja) | クラミドモナス・アシドフィラの抽出物、それを調製するための方法ならびにそれを含んでなる化粧用組成物および皮膚用組成物 | |
| TWI666444B (zh) | 以表皮絲胺酸消旋酶及／或ｄ－絲胺酸量為指標之皮膚之障壁機能促進藥劑之篩選方法及皮膚障壁機能評價方法 | |
| WO2015132917A1 (ja) | 表皮セリンラセマーゼ及び／又はｄ－セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 | |
| WO2015133591A1 (ja) | 表皮セリンラセマーゼ及び／又はｄ－セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 | |
| CN118695846A (zh) | 包括自发酵步骤的获得植物提取物的方法、包含此类提取物的组合物及其化妆品用途 | |
| KR20160028736A (ko) | 표피 세린 라세마아제 및/또는 d-세린 양을 지표로 하는, 피부 배리어 기능 항진 약제의 스크리닝 방법 및 피부 배리어 기능 평가 방법 | |
| FR2965357A1 (fr) | Utilisation cosmetique de la dermcidine, analogues ou fragments de celle-ci | |
| JP6113981B2 (ja) | スクリ−ニング方法 | |
| FR2965358A1 (fr) | Utilisation cosmetique de la dermcidine, analogues ou fragments de celle-ci | |
| JP6387220B2 (ja) | フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 | |
| JP2011093830A (ja) | 皮膚バリア機能改善剤 | |
| US20170152556A1 (en) | Methods for identifying circadian rhythm-dependent cosmetic agents for skin care compositions | |
| Kahsay | Formulation and characterization of colloidal formulations loaded with free amino acids for dermal delivery | |
| JP2022119185A (ja) | 抗光老化のための薬剤及び美容方法，並びに抗光老化剤のスクリーニング方法 | |
| CN119064602A (zh) | 包含测定9-hode的量的、皮肤的光老化的评价方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160311 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190305 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190709 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191009 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20191009 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191017 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20191029 |
|
| A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20191101 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20191112 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200707 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20201020 |
|
| C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20201020 |
|
| C302 | Record of communication |
Free format text: JAPANESE INTERMEDIATE CODE: C302 Effective date: 20210128 |
|
| C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210202 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210309 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210309 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210315 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6854073 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |